05 Study At Esmo 2023
July 20 (Reuters) - Lytix Biopharma AS LYTIX.OL :
* LYTIX BIOPHARMA ANNOUNCES PRESENTATION OF INTERIM DATA
FROM
ATLAS-IT-05 STUDY AT ESMO 2023
Source text for Eikon: ID:nObifymLQa
Further company coverage: LYTIX.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Lytix Biopharma AS
See all newsBrief: Lytix Biopharma Q3 Loss Widens To NOK 23.3 Mln
Brief: Lytix Biopharma Announces Interim Data On Neoadjuvant Treatment Of Melanoma
Brief: Lytix Biopharma Q1 Operating Loss Narrows To NOK 13.4 Mln
Brief: Lytix Biopharma Q4 Total Operating Income Nok 377,000
Brief: Lytix Biopharma Gets Notice Of Allowance For US Patent Application For Ltx-315 Clinical Program